Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation

BACKGROUND: Sarcomatoid renal cell cancer (RCC) is a distinct histological variant of RCC that is associated with rapid progression and a poor prognosis. The optimal treatment for patients with sarcomatoid RCC remains to be defined. Gemcitabine plus doxorubicine (GD) has shown some efficacy, however...

Descripción completa

Detalles Bibliográficos
Autores principales: Staehler, M, Haseke, N, Roosen, A, Stadler, T, Bader, M, Siebels, M, Karl, A, Stief, CG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351952/
https://www.ncbi.nlm.nih.gov/pubmed/20696639
http://dx.doi.org/10.1186/2047-783X-15-7-287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351952/
https://www.ncbi.nlm.nih.gov/pubmed/20696639
http://dx.doi.org/10.1186/2047-783X-15-7-287

Ejemplares similares